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A B S T R A C T
Rationale and objective: Stomach cancer mortality rates in Central and South America (CSA) are among the
highest in the world. We describe the current burden of stomach cancer in CSA.
Methods: We obtained regional and national-level cancer incidence data from 48 population-based
registries (13 countries) and nation-wide cancer deaths from WHO’s mortality database (18 countries).
We estimated world population age-standardized incidence (ASR) and mortality (ASMR) rates per
100,000 and estimated annual percent change to describe time trends.
Results: Stomach cancer was among the 5 most frequently diagnosed cancers and a leading cause of
cancer mortality. Between CSA countries, incidence varied by 6-fold and mortality by 5–6-fold. Males had
up to 3-times higher rates than females. From 2003 to 2007, the highest ASRs were in Chile, Costa Rica,
Colombia, Ecuador, Brazil and Peru (males: 19.2–29.1, females: 9.7–15.1). The highest ASMRs were in
Chilean, Costa Rican, Colombian and Guatemalan males (17.4–24.6) and in Guatemalan, Ecuadorian and
Peruvian females (10.5–17.1). From 1997 to 2008, incidence declined by 4% per year in Brazil, Chile and
Costa Rica; mortality declined by 3–4% in Costa Rica and Chile. 60–96% of all the cancer cases were
unspeciﬁed in relation to gastric sub-site but, among those speciﬁed, non-cardia cancers occurred 2–13-
times more frequently than cardia cancers.
Conclusion: The variation in rates may reﬂect differences in the prevalence of Helicobacter pylori infection
and other risk factors. High mortality may additionally reﬂect deﬁciencies in healthcare access. The high
proportion of unspeciﬁed cases calls for improving cancer registration processes.
ã 2015 International Agency for Research on Cancer; Licensee Elsevier Ltd. This is an open access article
under the CC BY-NC-ND IGO 3.0 license (https://creativecommons.org/licenses/by-nc-nd/3.0/igo/).
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Stomach cancer is one of the most common malignant
neoplasms worldwide [1–3]. In 2012, nearly 1 million new cancer
cases and 723,000 deaths were estimated to occur globally in both
males and females, making stomach cancer the ﬁfth most common
cancer diagnosis (after lung, breast, colorectal and prostate
cancers) and the fourth leading cause of cancer death (after lung,$ This is an Open Access article published under the CC BY NC ND 3.0 IGO license
which permits users to download and share the article for non-commercial
purposes, so long as the article is reproduced in the whole without changes, and
provided the original source is properly cited. This article shall not be used or
reproduced in association with the promotion of commercial products, services or
any entity. There should be no suggestion that IARC endorses any speciﬁc
organisation, products or services. The use of the IARC logo is not permitted. This
notice should be preserved along with the article’s original URL.
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1877-7821/ã 2015 International Agency for Research on Cancer; Licensee Elsevier Ltd
creativecommons.org/licenses/by-nc-nd/3.0/igo/).breast and liver cancers) [4]. More than 70% of the total number of
cases occurred in less developed regions of the world (677,000 new
cases and 548,000 deaths) and less than 30% of the cases occurred
in more developed regions (275,000 new cases and 175,000
deaths) [4]. The age-standardized incidence rates of stomach
cancer vary by 5- to 10-fold through the world, and the male-to-
female ratio is 2:1 [4,5]. Eastern Asia and South America have the
highest incidence rates in the world, whereas North America,
Western Africa and South-Central Asia have the lowest rates [6].
Mortality rates of stomach cancer in Central and South America
(CSA) are highest along the Paciﬁc coast, with the highest mortality
rates (from 12.4 to 22.3 per 100,000) in the mountains of the Andes
(from Chile to Venezuela) and the Sierra Madre Mountains in
Central America (from Costa Rica to southern Mexico) [7]. The
worldwide variation in stomach cancer incidence and mortality
rates reﬂect differences in the distribution of the factors associated
with this disease across the world [5,8]. Moreover, stomach cancer
rates, within any population, tend to be higher in those who are
relatively poorer and more socioeconomically deprived [9].. This is an open access article under the CC BY-NC-ND IGO 3.0 license (https://
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declining over the past decades in nearly all populations,
regardless of the background risk of stomach cancer. The declines
are thought to be due to declines in the prevalence of Helicobacter
pylori (H. pylori) infection and improvements in sanitation and
preservation and storage of foods and other dietary factors (high
consumption of fruit and vegetables, reduced salt consumption).
Changes in tobacco smoking may also play a role [8,10–12]. Despite
the observed declines in incidence, the absolute burden of stomach
cancer remains particularly high in several Asian and Central and
South American (CSA) countries [5,8].
Although stomach cancer is usually reported as a single entity, it
can be classiﬁed according to its anatomic location into cardia
(CGC) and non-cardia (NCGC), and according to its histological
pattern into intestinal (well-differentiated) and diffuse (undiffer-
entiated) types [13–15]. These two classiﬁcations are currently
used because their epidemiology, biology, clinical features,
pathology, and precursor lesions are particular for each subtype
[14–16]. Recent global estimates revealed that 87% of all stomach
cancer cases diagnosed in 2012 were NCGC, with most of the cases
occurring in Eastern Asia (61%) followed by Central Asia (10%),
Eastern Europe (7.5%), and South America (7.0%) [3]. In 2012, the
estimated incidence of CGC varied by about 3-fold in both males
and females across world regions; the incidence of NCGC varied by
nearly 8-fold in males and by 4.5 in females [17]. Global estimates
indicate that 89% (774,000) of the NCGC cases that occurred in
2008 were attributable to H. pylori infection [18]. This is
particularly concerning for CSA given the high prevalence of H.
pylori infection, ranging from 50 to 95% [19–21].
Despite the reported declines in the incidence and (mainly)
mortalityof stomach cancer inCSA inthe last few decades [1,2,12,22–
28], CSA has some of the highest incidence and mortality rates in the
world [4,29,30]. Recent projections indicate that the burden of
stomach cancer in CSA will increase by approximately 80% by the
year 2030 (102,000 newcases and 88,000 deaths); such increases are
expected to be driven primarily by the growth and ageing of the
population [4]. Given that the descriptive epidemiology of stomach
cancer in many CSA countries is limited, we aim to describe the most
current geographical and temporal trends in incidence and mortality
of stomach cancer in the CSA region and present a description of the
distribution of incident cases by anatomic site and histological
subtype by sex. We interpret the results based on the known
determinants of stomach cancer.
2. Methods
The present analysis includes stomach cancer (C16), as coded by
the 10th edition of the International Classiﬁcation of Diseases for
Oncology (ICD-10). The data sources and methods are described in
detail in an earlier article in this supplement (Sierra and Forman).
In brief, we obtained regional- and national-level incidence data
from 48 population-based cancer registries in 13 countries, and
(nationwide) cancer deaths from the World Health Organization
mortality database for 18 countries. We estimated age-standard-
ized incidence (ASR) and mortality (ASMR) rates perTable 1
Countries included in the analysis of time trends.
Country Names of registries included Period % of the population
covered
Argentina Bahia Blanca 1993–2007 0.8
Brazil Aracaju, Fortaleza, Goiania,
Sao Paulo
1997–2006 8.0
Chile Valdivia 1993–2008 2.2
Costa Rica National registry 1985–2007 100.0100,000 person-years using the direct method and the world
standard population [31,32]. We estimated national ASRs by
aggregating the data from the available cancer registries using a
weighted average of local rates. To describe incidence and
mortality time trends, we calculated the estimated annual
percentage change (EAPC) for four countries (Table 1) using the
method proposed by Esteve et al. [33]. All of the EAPCs were tested
for equality to zero by using the corresponding standard errors. We
considered EAPCs statistically signiﬁcant if the P-value 0.05. We
conducted all analyses in Stata version 12.1 (StataCorp) [34].
In addition, we estimated the incidence of stomach cancer by
anatomic location as cardia (C16.0), non-cardia (fundus (C16.1),
corpus (C16.2), antrum (C16.3), pylorus (C16.4), lesser curvature
(C16.5), and greater curvature (C16.6), and other – overlapping
lesions (C16.8) and unspeciﬁed (C16.9) – as classiﬁed in Cancer
Incidence in Five Continents (CI5) [6]. We also evaluated the
distribution of tumors by histological type [35] as intestinal (ICD-
O-3 codes M8010, M8140, M8144, and M8211), diffuse (codes
M8490, M8142, and M8145), and other epithelial (all other
histology codes excluding M8800–M9759 and M8000–M8004)
using the same classiﬁcation as in other studies [36–38].
3. Results
3.1. Age-standardized incidence and mortality rates
During the most recent 5-year period evaluated, stomach
cancer was one of the ﬁve most frequently diagnosed cancers in
Argentina, Brazil, Bolivia, Chile, Colombia, Costa Rica, Ecuador, El
Salvador, French Guyana, and Peru and one of the ﬁve leading
causes of cancer death in most CSA countries (except for females in
Argentina, Cuba, and Suriname). Overall, males had incidence and
mortality rates 1.3–2.8 times higher than females (Table 2).
The incidence of stomach cancer varied by 6-fold across
countries in CSA. In males, the highest incidence rates were
observed in Chile (29.1) followed by Costa Rica, Colombia, Ecuador
and Brazil, and Peru (ASRs ranging from 19.2 to 26.5) while the
lowest rates were observed in Mexico, Bolivia and El Salvador (3.3–
4.6). In females, the highest ASRs were seen in Peru, Costa Rica,
Ecuador, Colombia, Chile and Brazil (9.7–15.1) and the lowest rates
were in Mexico, Bolivia and El Salvador (ASRs 3.0) (Table 2).
Mortality rates of stomach cancer varied by 5–6-fold in CSA. In
males, the highest mortality rates were observed in Chile and Costa
Rica (ASMRs: 20.1–24.6) followed by Colombia and Guatemala
(17.4–17.8) and the lowest rates were in Suriname, Cuba and
Paraguay (5.0–7.1). In females, the highest ASMRs were seen in
Guatemala (17.1) followed by Ecuador and Peru (10.5–11.2) and the
lowest rates were in Paraguay, Argentina, Cuba and Suriname (2.9–
3.9) (Table 2).
3.2. Age-speciﬁc rates
Stomach cancer incidence and mortality were strongly related
to age. In the majority of CSA countries, 80–97% of all the stomach
cancer cases were diagnosed in older men and older women
(50 years) and 3–18% were diagnosed in younger men and
women (<50 years) in the most recent 5-year period. In Bolivia and
Mexico, 21% and 19% of the cases, respectively, were diagnosed in
younger men. In French Guyana, El Salvador, Mexico, and Costa
Rica 20–25% of the cases were diagnosed in younger women. The
mean age at diagnosis across CSA countries ranged from 61 to
68 years in males and from 59 to 73 years in females (data not
shown).
Incidence rates slowly increase after age 40–44 years and
gradually increase with advanced age, reaching a peak around age
75 years (Figs.1 and 2). Stomach cancer mortality rates followed a
Table 2
Age-standardized incidence and mortality rates (per 100,000) from stomach cancer in Central and South America, all ages.
Country (period) Sex Incidence Mortality
Cases Crude Rate ASR (W) M:F MV% Ranka Deaths Crude Rate ASR (W) M:F Ranka
Central America
Belize (2003–07) M 38 5.5 9.8 1.6 3
F 29 4.1 6.1 5
Costa Rica (2003–07) M 2380 22.0 26.5 1.8 80 2 1866 17.1 20.1 2.1 1
F 1512 14.4 15.0 80 2 995 9.4 9.4 2
Cubab (2004–07) M 206 12.6 8.0 2.0 67 7 1967 8.7 6.2 2.0 5
F 119 7.4 4.0 60 11 1161 5.2 3.2 9
El Salvadorb (1999–03) M 369 2.8 3.7 1.8 86 1 1265 8.8 11.8 1.4 1
F 252 1.8 2.0 88 2 1176 7.6 8.6 4
Guatemala (2003–07) M 3234 10.4 17.4 1.0 1
F 3636 11.2 17.1 1
Mexicob (2006–10) M 643 3.8 4.6 1.5 100 5 14474 5.2 8.4 1.4 4
F 482 2.7 3.0 100 11 12509 4.2 5.8 5
Nicaragua (2003–07) M 726 5.4 9.3 1.6 2
F 544 4.0 6.0 2
Panama (2003–07) M 717 8.8 10.4 1.6 3
F 494 6.2 6.4 3
South America
Argentinab (2003–07) M 1748 14.2 14.0 2.5 71 4 9564 10.1 8.7 2.6 4
F 902 7.0 5.5 63 9 5088 5.2 3.3 7
Boliviab (2011) M 38 2.9 3.3 1.3 100 4
F 32 2.4 2.6 91 7
Brazilb (2003–07) M 8964 16.1 21.2 2.2 79 4 40343 8.8 10.5 2.4 3
F 6065 9.8 9.7 78 7 21585 4.6 4.5 4
Chileb (2003–07) M 623 26.6 29.1 2.8 82 3 10215 25.3 24.6 2.8 1
F 262 11.8 10.3 78 6 5095 12.4 8.9 4
Colombiab (2003–07) M 2028 22.4 25.3 2.0 85 2 13492 12.7 17.8 1.9 1
F 1407 14.0 12.7 81 4 9072 8.3 9.3 4
Ecuadorb (2003–07) M 900 19.0 22.7 1.5 79 2 4262 12.7 15.8 1.4 1
F 764 14.9 14.7 73 4 3406 10.2 11.2 1
French Guyanab (2003–08) M 53 10.7 16.9 1.9 100 4
F 32 6.4 9.0 94 5
Paraguay (2003–07) M 716 4.8 7.1 1.7 3
F 431 3.0 3.9 3
Perub (2001–05) M 1629 17.7 19.2 1.3 76 2 6110 9.1 12.4 1.0 1
F 1492 15.5 15.1 71 3 6061 9.0 10.5 1
Suriname (2003–07) M 49 3.9 5.0 1.4 4
F 34 2.7 2.9 7
Uruguay (2005–07) M 960 20.0 14.3 2.1 80 6 776 16.1 11.3 1.6 3
F 648 12.6 6.7 77 9 487 9.4 4.5 5
Venezuela (2003–07) M 5498 8.2 11.3 1.6 3
F 3453 5.2 6.1 4
ASR (W), age-standardized (World population) rate per 100,000; M, males; F, females; M:F, male-to-female ratio (female, reference).
a Rank across cancer types, based on highest ASR excluding: all sites but C44 and all sites.
b Incidence rates were estimated using data from regional cancer registries.
S64 M.S. Sierra et al. / Cancer Epidemiology 44S (2016) S62–S73similar pattern. Age-speciﬁc mortality rates began to increase after
age 45 years in both sexes, followed by a sharp increase from ages
60–64 and 65–69 years, with the highest mortality rates observed
among older age groups (Figs. 1 and 2). In general, incidence and
mortality rates in males were higher than in females in most agegroups, after the age of 35–39 years. The male-to-female (M:F)
incidence and mortality ratios were 1:1 in young age groups
(<40 years), then increased to 2–4:1 for ages 50–69 years, and then
M:F ratios declined to about 2:1 after age 70+ years (Fig. 3).
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Fig. 1. Male age-speciﬁc rates (per 100,000) of stomach cancer in Central and South America.
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Fig. 2. Female age-speciﬁc rates (per 100,000) of stomach cancer in Central and South America.
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Fig. 3. Age-speciﬁc incidence rates (per 100,000) among males (blue) and females (red) for selected countries.
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In the four countries evaluated (Argentina, Brazil, Chile and
Costa Rica), stomach cancer rates have been declining since the
1990s in both males and females (Fig. 4). In males, the incidence of
stomach cancer declined, signiﬁcantly, on average 3.9–4.4% per
year in Costa Rica, Chile and Brazil for the period from 1997 to
2008; mortality rates declined on average 4.4% per year in Costa
Rica and by 3.3% in Chile for the same time period (Fig. 5). Mortality
rates among Argentinean males declined by 2% annually, although
not signiﬁcantly, whereas incidence rates remained constant. In
females, the greatest declines in incidence and mortality for the
period 1997–2008 were seen in Costa Rica (EAPC: 3.5% for
incidence and EAPC: 4.6 for mortality) and Chile (EAPC: 3.4% for
both incidence and mortality); rates also declined in Argentina and
Brazil; however, the declines did not reach statistical signiﬁcance
(Fig. 5).
3.4. Distribution of gastric cancer cases by anatomic subsite
In the most recent 5-year period, about 80% of all the
stomach cancer cases diagnosed in CSA were classiﬁed as other
(C16.8–C16.9), ranging from 34 to 93% in males and 31–96% in
females; 16% of the cases were classiﬁed as non-cardia gastriccancers (NCGC) and 5% were classiﬁed as cardia gastric cancers
(CGC).
Table 3 shows the frequency distribution of CGC and NCGC in
CSA. In general, NCGC was 2–7 times and 2–13 more frequently
diagnosed in males and females, respectively, than CGC, except for
males in Cuba, El Salvador, Chile, and Uruguay where a similar
proportion of CGC and NCGC were diagnosed. In males, the
proportion of CGC cases ranged from 12 to 58% (except in Mexico,
0%) and the proportion of NCGC cases ranged from 42% to 88%
(except in Mexico, 100%). In females, the corresponding propor-
tions for CGC and NCGC cancers were 7–40% (except in Mexico, 0%)
and 60–93% (except in Mexico, 100%), respectively.
3.5. Distribution of gastric cancer cases by histology
Approximately 79% (range 65–80%) of all the stomach cancer
cases diagnosed in CSA in the most recent 5-year period were
classiﬁed as intestinal, diffuse, or other epithelial subtype, and
about 21% (range 18–40%) corresponded to histology code 8000
(malignant tumor not otherwise speciﬁed) (data not shown).
Table 4 shows the distribution of gastric cancers in CSA by
histological type. The intestinal subtype was 2–7 times more
common than the diffuse type. Approximately 50–80% of all the
cases diagnosed in both sexes were of intestinal type, 8–35% were
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Fig. 5. Estimated annual percentage change in age-standardized incidence and mortality rates (per 100,000) of stomach cancer by sex.
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Table 3
Distribution of cardia gastric cancers (CGCs) and non-cardia gastric cancers (NCGCs), by sex, in Central and South America.
Country (period) Males Females
CGC NCGC NCGC/CGC CGC NCGC NCGC/CGC
n(%) n(%) n(%) n(%)
Central America
Costa Rica (2003–07) 182 (22) 659 (78) 4 54 (11) 447 (89) 8
Cubay (2004–07) 8 (53) 7 (47) 1 2 (40) 3 (60) 2
El Salvadora (1999–03) 19 (58) 14 (42) 1 3 (14) 18 (86) 6
Mexicoa (2005–10) 0 (0) 59 (100) – 0 (0) 49 (100) –
South America
Argentinaa (2003–07) 63 (28) 162 (72) 3 17 (16) 87 (84) 5
Boliviaa (2011) 4 (33) 8 (67) 2 3 (21) 11 (79) 4
Brazila (2003–07) 525 (32) 1100 (68) 2 195 (20) 791 (80) 4
Chilea (2003–07) 47 (42) 66 (58) 1 13 (29) 32 (71) 2
Colombiaa (2003–07) 198 (36) 350 (64) 2 76 (24) 245 (76) 3
Ecuadora (2003–07) 48 (17) 233 (83) 5 15 (7) 197 (93) 13
French Guyanaa (2003–08) 5 (12) 36 (88) 7 2 (7) 25 (92) 13
Perua (2001–05) 84 (16) 439 (84) 5 33 (8) 379 (92) 11
Uruguay (2005–07) 65 (53) 58 (47) 1 20 (35) 37 (65) 2
a Number of cases and percentages were estimated using aggregated data from regional cancer registries.
Table 4
Distribution of gastric cancers by histology in Central and South America.
Males Females
Intestinal Diffuse Other epithelial Intestinal Diffuse Other epithelial
n (%) n (%) n (%) n (%) n (%) n (%)
Central America
Costa Rica (2003–2007) 1285 (54) 328 (14) 218 (9) 724 (48) 288 (19) 162 (11)
Cubaa (2004–2007) 115 (56) 0 (0) 8 (4) 60 (50) 1 (1) 4 (3)
El Salvadora (1999–2003) 234 (63) 56 (15) 13 (4) 156 (62) 50 (20) 6 (2)
Mexicoa (2005–2010) 521 (67) 193 (25) 44 (6) 367 (62) 170 (29) 39 (7)
South America
Argentinaa (2003–2007) 999 (57) 241 (14) 104 (6) 435 (48) 136 (15) 61 (7)
Boliviaa (2011) 30 (79) 7 (18) 1 (3) 23 (72) 5 (16) 0 (0)
Brazila (2003–2007) 5566 (62) 935 (10) 676 (8) 3456 (57) 863 (14) 467 (8)
Chilea (2003–2007) 336 (54) 85 (14) 82 (13) 126 (48) 54 (21) 23 (9)
Colombiaa (2003–2007) 1248 (62) 350 (17) 56 (3) 739 (53) 317 (23) 34 (2)
Ecuadora (2003–2007) 513 (57) 180 (20) 12 (1) 387 (51) 161 (21) 2 (0)
French Guyanaa (2003–2008) 33 (51) 23 (35) 6 (9) 16 (42) 12 (32) 6 (16)
Perua (2001–2005) 765 (47) 340 (21) 131 (8) 554 (37) 397 (27) 97 (7)
Uruguay (2005–2007) 591 (62) 77 (8) 90 (9) 330 (51) 99 (15) 42 (6)
a Number of cases and percentages were estimated using aggregated data from regional cancer registries.
M.S. Sierra et al. / Cancer Epidemiology 44S (2016) S62–S73 S69of diffuse type (except in Cuba, 0–1% diffuse type cases), and 0–13%
were of other or epithelial type. Male-to-female ratios were 1–
3:1 for intestinal type, 1–2:1 for diffuse type, and 1–6:1 for
epithelial type.
4. Discussion
In this study we aimed to describe the current burden of
stomach cancer in CSA. Stomach cancer continues to be one of the
ﬁve leading causes of cancer diagnosis and cancer death in both
males and females in most countries within the region. There was a
remarkable variation in stomach cancer incidence and mortality
rates across CSA (6-fold and 5–6-fold, respectively). Overall, males
had incidence and mortality rates 1.3–2.8 times higher than those
in females. The high incidence rates observed in Chile (males),
Costa Rica, Colombia, Ecuador, Brazil (males) and Peru (females)
were lower than the incidence rates reported in other regions of
the world where the burden of stomach cancer remains very high,such as China (ASRs: 45–68 for 2003–2007), yet these rates were
up to 3 times higher than the rates reported for Hispanics in the US
(9.4 for males and 5.9 for females) [6].
Mortality rates of stomach cancer in CSA were among the
highest in the world. Chilean males had the fourth highest
mortality rates in the world for the period 2003–2007, following
the Republic of Korea, the Russian Federation and Kazakhstan
(ASMRs: 24.8–27.7) [29]. Guatemalan females had the highest
mortality rates in the world between 2003 and 2007. Females in
Ecuador, Peru, Colombia, and Costa Rica also had some of the
highest mortality rates in the world, ranking third, sixth, seventh,
and tenth, respectively [29]. The low mortality rates observed in
Paraguay, Argentina, Cuba and Suriname were about twice as high
as the mortality rates in the US (3.8 for males and 1.6 for females for
the period 2003–2007) [29]. The extremely high mortality rates in
CSA may reﬂect poor access to healthcare. A study from Chile
showed that most stomach cancer cases are diagnosed late (12%
identiﬁed via death certiﬁcations, 20% at an inoperable stage) and
S70 M.S. Sierra et al. / Cancer Epidemiology 44S (2016) S62–S73only 6% were diagnosed early (stages I or II). These percentages
were much lower that the proportion of cases diagnosed early in
other regions (i.e. 37% in Florence, Italy and 31% in China) [39].
The incidence of stomach cancer observed in both males and
females in CSA in the most recent 5-year period was lower than the
incidence rates previously reported for Brazil, Colombia, Costa
Rica, Ecuador, and Peru for earlier time periods (1998–2002)
[1,40,41]. The observed mortality patterns of stomach cancer for
both sexes were generally consistent with those in recent reports
[24,42]; however, the observed rates were lower when compared
with mortality rates from earlier periods (i.e.1990s) [40,43,44]. The
declines in the incidence and mortality of stomach cancer observed
in Argentina, Brazil, Chile and Costa Rica in 1997–2008 coincide
with declines in stomach cancer reported in other CSA regions in
the last few decades [1,2,12,22–28] which may in part be explained
by declines in the prevalence of H. pylori infection and by
improvements in sanitation and in the preservation and storage
of foods [1,2,8,10,11,45]. Death certiﬁcations for gastric cancer are
“sufﬁciently reliable” particularly among those below 65 years of
age [12,26,43]; thus the observed changes in mortality trends may
not be impacted by the validity of death certiﬁcations [26].
It has been reported that Hispanics in the US are more
frequently diagnosed with stomach cancer at younger ages
(<50 years) than any other ethnic group (21% versus 7–16%)
[46,47]. In the most recent 5-year period, a comparable proportion
of cases were diagnosed in younger men in Bolivia and Mexico (19–
21%) and in younger women in French Guyana, El Salvador, Mexico,
and Costa Rica (20–25% diagnosed in young women); however, in
most CSA countries the vast majority of the stomach cancer cases
(80–97%) were diagnosed in older populations (50 years). Recent
data from CI5 showed an age-speciﬁc incidence pattern across
different ethnic groups in the US that is similar to the one described
in the present report. Although Hispanics, Blacks and Asian-Paciﬁc
Islanders had higher stomach cancer rates than non-Hispanic
Whites and Whites, stomach cancer was relatively rare in males
and females under 45 years of age; incidence rates slowly
increased with age and attained the highest rates at ages of 60
years and above [4].
Despite the geographic variation in stomach cancer rates,
incidence and mortality rates were higher in males than females in
most age groups after the age of 35–39 years. The general age-
speciﬁc pattern of the M:F ratios was from low-to-high-to-low,
which is consistent with other reports [9,48,49]. The widest gap
between sexes was observed between the ages of 50 and 69 years
(M:F incidence and mortality ratios of about 2–4:1). Although the
reasons for the sex disparities in stomach cancer risk are unclear, it
has been suggested that female sex-speciﬁc hormones may play a
protective role [50]. The sex difference may also reﬂect the lag in
age at intestinal type adenocarcinoma onset in females as
compared to males [51].
Only a few established factors are known to increase the risk of
stomach cancer; these include age, sex, family history of the
disease, radiation, H. pylori infection and smoking [5,52]. Despite
the high relative risk, family history and radiation may explain only
a small proportion of the cases observed in CSA given their low
prevalence in the general population [5,8].
Infection with H. pylori, a major determinant of stomach cancer,
probably contributed to the high rates of stomach cancer observed
in CSA [17,18]. The prevalence of H. pylori infection varies widely
between and within countries and differs by age, race/ethnicity,
migration from high-prevalence areas, and by indicators of low
socioeconomic status (crowding, education level, lack of proper
sanitation and safe drinking water, and poor diets) [53,54]. In
South America, for example, the prevalence of H. pylori infection
among adults ranges from 50% to 95% (50–90% in the developing
world) [19–21].It is possible that tobacco smoking contributed to some extent
to the geographic variation in stomach cancer rates across CSA, and
may partially explain the observed disparity in cancer rates
between males and females [30,55]; however, Freedman et al. [56]
suggested that the high rates of upper gastrointestinal cancers
among males could not be explained by differences in smoking
history. It has been estimated that approximately 10% (or more) of
the stomach cancer deaths in parts of Latin America, the Western
Paciﬁc and Eastern Europe were due to smoking [57]. In Latin
America (including the Caribbean), tobacco smoking has increased
over the last few decades, particularly among females [58]. In CSA,
the prevalence of any tobacco smoking in 2011 among males
ranged between 20% (in Guatemala) and 44% (in Chile) and among
females from 2% (in Guatemala and Belize) to 38% (in Chile) [59].
Moreover, smoking has been shown to “potentiate the carcino-
genic effect of infection with cagA-positive H. pylori” [5].
Although we were unable to estimate the incidence of stomach
cancer by anatomic location or histological type due to the large
percentage of unspeciﬁed cases, we observed that NCGCs were 2–
13 times more frequently diagnosed in most CSA countries than
CGCs in both sexes. The consistent observation was the male
predominance of any anatomic subtype as compared to females.
Additionally, the distribution of NCGC was the highest in countries
where the incidence of stomach cancer was also the highest, such
as Chile, Costa Rica, Colombia, Ecuador, Brazil, and Peru. Given the
high prevalence of H. pylori in CSA and the strong association
between H. pylori and NCGC [60], we expected to see a higher
proportion of incident NCGC cases than CGCs. Similarly, a high
proportion of NCGC cases was reported in four Central American
countries as well as Hispanics in the US, and Hispanics born in
Central America (80–86%) [38]. Our observations were consistent
with previous studies as well [12,17].
We also noted that intestinal subtype was the most frequent
histological classiﬁcation in CSA (representing about 50–80% of the
total), being 2–7 times more common than the diffuse type in both
sexes. Similarly, Corral et al. [38] reported that in four Central
American countries 64% of the stomach cancer cases were of the
intestinal subtype; in contrast, only 31% of cases diagnosed among
Hispanics in the US were of the intestinal subtype. Both intestinal
and diffuse types are also related to H. pylori infection [21].
Declines in the incidence of intestinal type and diffuse type have
been reported in the US in recent years, which is consistent with
the declines in H. pylori infection [61].
Limited evidence from intervention studies suggests that
eradication of H. pylori infection may reduce the risk of developing
gastric cancer [62,63]. H. pylori resistance to different antibiotics is
a major concern in CSA given the widespread use of antibiotics in
the region [64,65]. Currently, there are no national screening
programs for the prevention of gastric cancer in CSA [66]. In 2006,
the Chilean Ministry of Health initiated an opportunistic national
screening program for gastric cancer, offering endoscopic exami-
nation to patients older than 40 years with dyspeptic symptoms
and with an immediate family member with history of gastric
cancer; H. pylori eradication therapy is recommended in any
patient undergoing endoscopy with duodenal or stomach ulcers,
atrophic gastritis, lymphoma, adenoma, gastric cancer, and family
history of gastric cancer [66]. Two studies conducted in Costa Rica
and Venezuela using x-rays for screening yielded contradictory
results on its impact in reducing stomach cancer mortality [67,68].
The intervention study conducted in Cartago, Costa Rica, during
1998–2000 showed a reduction in gastric cancer mortality of about
50%, but the high cost of this intervention is an obstacle for its
implementation on a larger scale [67]. In contrast, a case–control
study of gastric cancer screening using X-rays conducted in Tachira,
Venezuela, in 1980, revealed no changes in stomach cancer
mortality [68].
M.S. Sierra et al. / Cancer Epidemiology 44S (2016) S62–S73 S71Other factors possibly associated with an increased risk of
stomach cancer are: alcohol consumption [30,69–71], salt and salt-
preserved foods [30,72], consumption of processed meat [30,73],
obesity [72,74–77], attained height [16,78–81], Epstein–Barr virus
(EBV) [8,30,60,82], and pernicious anemia [8]. In contrast, factors
probably inversely associated with stomach cancer are: non-
starchy vegetables (allium vegetables) and fruits [72], increased
physical activity [83] and non-steroidal anti-inﬂammatory drug
use, including aspirin [30,82,84–86]. Moreover, diet, smoking and
alcohol are related to NCGC, whereas obesity, gastroesophageal
reﬂux, and Barrett’s esophagus are associated with CGC [14–16].
However, the extent to which these factors contributed to the
observed variation in stomach cancer rates in CSA remains
uncertain.
The present study has several strengths and limitations. We
used the most up-to-date available data to present a comprehen-
sive description of the burden of stomach cancer in 13CSA
countries (48 cancer registries), more than the data published in
the latest volume of CI5 (eight countries, 22 cancer registries) [6]
and national mortality data from 18 countries. However, our
results should be interpreted with caution because in most
countries cancer incidence data are represented by aggregated
data from regional registries which do not cover the entire country
(except for Costa Rica and Uruguay). Registrations may also differ
in completeness and data quality due to the age and development
in maturity of the registries, and this could explain the strikingly
low incidence rates observed in Bolivia and El Salvador. We did not
estimate incidence rates by anatomic site because the rates would
have been underestimated due to the large percentage of cases
(60–96% of the total) classiﬁed as unspeciﬁed (C16.9). Similarly, we
did not estimate the incidence rates by histological type given that
18–40% of cases had histology code M8000, malignant tumor not
otherwise speciﬁed. Disparities in the classiﬁcation of tumors in
the gastroesophageal region have been described in Sweden, a
country with a high-quality cancer registry, because of the
difﬁculty in distinguishing between whether the tumor originated
from the gastric cardia or the esophagus [87], and such disparities
in disease classiﬁcation may bias the estimation of rates [88].
While the difﬁculties in classifying some of these tumors may
persist, particularly by anatomic site, improvements in stomach
cancer registrations of both histological type and anatomic sites in
CSA are needed in order to minimize missing or incomplete data.
5. Conclusion
Stomach cancer is one of the most frequently diagnosed
cancers and among the leading causes of cancer death in both
males and females in several countries of CSA, after prostate,
breast, cervix, colorectum and lung cancers. Stomach cancer rates
varied widely across CSA (6-fold for incidence and 5–6-fold for
mortality) and males had up to 3 times higher incidence and
mortality rates than females. The highest incidence of stomach
cancer was seen in Chile (males), Costa Rica, Colombia, Ecuador,
Brazil (males) and Peru (females). Mortality rates in CSA were
among the highest in the world, particularly among Guatemalan
females (ranking ﬁrst) and Chilean males (ranking fourth). From
1997 to 2008, incidence declined by about 4% per year in Brazil,
Chile and Costa Rica in 1997–2008, and mortality declined by
about 3–4% in Costa Rica and Chile, although statistically
signiﬁcant declines were seen for males but not for females.
According to the anatomic site, NCGC were 2–13 times more
frequently diagnosed in CSA than CGC. According to histological
deﬁnition, 50–80% of the cases were of intestinal subtype, and
this subtype was 2–7 times more common than diffuse type in
both sexes. The overall geographic and temporal variation of
stomach cancer rates observed in CSA may in part be explained bydifferences in the prevalence of H. pylori infection and by
improvements in sanitation and the preservation and storage of
foods. Smoking patterns could also explain some of the geographic
variations and sex disparities. However, the extent to which other
presumed factors contributed to the observed variation in stomach
cancer rates in CSA remains uncertain. The extremely high
mortality of stomach cancer may reﬂect deﬁciencies in access
to healthcare in CSA and highlights the need to focus efforts on the
prevention and management of this disease.
The large percentage of stomach cancer cases classiﬁed as
unspeciﬁed (60–96% for anatomic site and 18–40% for histological
subtype) highlights the need to improve cancer registration
processes for both histological type and anatomic sites in CSA in
order to minimize missing or incomplete data, allowing an
understanding of the descriptive epidemiology of stomach cancers
in more detail.
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